FTC Sues Hims & Hers Over Health Data Sharing and Deceptive Billing — Shares Sink 12%

Event Analysis

The U.S. Federal Trade Commission, joined by Los Angeles County and the State of Utah, has filed a federal lawsuit against Hims & Hers Health Inc. (NYSE: HIMS) in California federal court, according to Reuters and Bloomberg Law. The complaint alleges the telehealth platform shared users' sensitive health data with online advertisers — specifically Meta Platforms and Snap — via tracking technologies, despite explicit privacy promises to users. Additionally, the FTC alleges Hims charged customers for prescriptions before consultations occurred and deliberately made subscription cancellations difficult, practices regulators classify as deceptive billing and so-called "dark patterns."

This escalation is significant because it moves HIMS from regulatory scrutiny to formal litigation. The FTC first requested information from Hims in October 2023, and Bloomberg reported an active investigation in August 2025 — each headline already moved the stock. Now that probe has crystallized into a binding legal action with state co-plaintiffs, raising the stakes considerably: formal suits carry the risk of monetary penalties, mandatory business practice changes, and court-ordered restitution.

What makes this particularly damaging is the timing. HIMS already carries a heavy legal overhang — a securities class action over its compounded semaglutide marketing (Case 25-cv-05315) and a recently resolved Novo Nordisk patent dispute remain part of its story. The FTC action lands into that cluster, reinforcing a narrative that Hims' aggressive direct-to-consumer growth model has attracted multi-front regulatory attention. This is part of the broader Global Regulatory Enforcement Wave targeting consumer health subscription businesses and health data privacy practices.

The data-sharing allegations are particularly pointed: health data — covering mental health, sexual health, and weight loss — carries exceptional sensitivity. Regulators disclosing that such data flowed to Meta and Snap via tracking pixels signals an industry-wide reckoning for telehealth apps that rely on third-party ad infrastructure.

What This Means for Traders

According to Bloomberg Law, HIMS shares fell as much as 10% intraday after the suit was filed; live market data confirms the stock is currently trading at $25.75, down 11.90% on the day, with an intraday low of $24.79. Sentiment is sharply bearish in the near term. Traders should anticipate elevated volatility as analysts reprice the regulatory risk premium — potential outcomes range from monetary fines and restitution to court-mandated changes in data tracking and subscription flows, each of which would directly impact customer acquisition cost, lifetime value, and margins.

Beyond HIMS itself, the sector signal matters. The FTC's focus on health data sharing and cancellation dark patterns represents a compliance warning to the broader DTC telehealth space. Traders with positions in health-tech adjacent names — or watching the GLP-1 distribution theme through stocks like Novo Nordisk A/S — should factor in rising sector-wide compliance costs and potential multiple compression. The broader S&P 500 Index and NASDAQ 100 Index implications are minimal at the single-stock level, but the regulatory tone is a mild headwind for high-multiple consumer health-tech names.

Meta and Snap are named in the factual record as recipients of user health data but are not primary defendants. Any incremental regulatory narrative impact on their valuations is likely immaterial given their scale, but traders in those names should monitor whether the FTC's findings prompt follow-on scrutiny of ad-tech platforms handling medical data.

Trade Hims & Hers Health, Inc. on CoinUnited.io

Trade HIMS with up to 800xx leverage → | Create Free Account